Biologics and Nutrition Treatment for Active Crohn's in Young People
Part of Digestive system clinical trials.
This study tests whether combining biologic medicines (TNF-alpha inhibitors like infliximab or adalimumab) with a special nutrition plan helps young people with active Crohn's disease feel better. The nutrition plan may include drinking special formula drinks instead of regular food (or alongside some regular food).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 6 to 18 years old with active Crohn's disease (confirmed by blood/stool tests or symptom scores)
- Starting biologic treatment (infliximab or adalimumab) as your doctor recommends
- Able to participate in a nutrition-based treatment plan that may involve formula drinks
- Not currently on high-dose steroids (more than 20 mg/day prednisone or 9 mg/day budesonide)
- No stoma, short bowel syndrome, severe fistulas, or strictures requiring surgery
- No anorexia nervosa, untreated TB, HIV, or Hepatitis B/C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a specially designed anti-inflammatory American diet can help control mild to moderate Crohn's Disease symptoms. Participants will follow a diet plan, with guidance from the research team, to see if it reduces inflammation and improves quality of life.
This study tests whether starting adalimumab along with partial enteral (tube or drink) nutrition helps control active Crohn’s disease. It may help reduce symptoms and inflammation compared with standard care alone.
This study tests a modified version of the Crohn's Disease Exclusion Diet (CDED) that uses Nordic foods to see if it works as well as the standard CDED diet in children with mild-to-moderate Crohn's disease. It looks for ways to reduce inflammation without using steroids.
This study tests if a special diet (called CDED) combined with infliximab (a biologic drug) is more effective than infliximab alone for children with newly diagnosed or relapsed moderate-to-severe Crohn’s disease. It aims to improve gut healing and reduce inflammation.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This study tests whether a specific “exclusion diet” (removing certain foods) added to standard treatment can better control unstable Crohn’s disease in children. It may help reduce inflammation and flare-ups when symptoms are not controlled by usual medicines.
Hear when a new Crohn's Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.